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Firefly luciferase (FLuc) is frequently used as a
reporter in high-throughput screening assays, owing
to the exceptional sensitivity, dynamic range, and
rapid measurement that bioluminescence affords.
However, interaction of small molecules with FLuc
has, to some extent, confounded its use in chemical
biology and drug discovery. To identify and charac-
terize chemotypes interacting with FLuc, we deter-
mined potency values for 360,864 compounds found
in the NIH Molecular Libraries Small Molecule
Repository, available in PubChem. FLuc inhibitory
activity was observed for 12% of this library with
discernible SAR. Characterization of 151 inhibitors
demonstrated a variety of inhibitionmodes, including
FLuc-catalyzed formation of multisubstrate adduct
enzyme inhibitor complexes. As in some cell-
based FLuc reporter assays, compounds acting as
FLuc inhibitors yield paradoxical luminescence
increases, thus data on compounds acquired from
FLuc-dependent assays require careful analysis as
described here.
INTRODUCTION
The reporter firefly luciferase from Photinus pyralis (FLuc) is
widely used in molecular biology and small molecule high-
throughput screening (HTS) assays (Fan and Wood, 2007). In
fact, 20% of assays found in PubChem—the publically available
small molecule screening database—utilize bioluminescence
(Thorne et al., 2010). The FLuc enzyme catalyzes the oxidation
of luciferin (D-LH2) to produce oxyluciferin and light through
the intermediate formation of a LH2-adenylated adduct from
ATP. Previous work has shown that several classes of
compounds found in chemical libraries act as inhibitors of this
enzymatic reaction (Auld et al., 2008a, 2009b; Thorne et al.,
2010). We have found that many inhibitors, such as the 3,5-diaryl
oxadiazole class of inhibitors, although lacking obvious struc-
tural similarity to the D-LH2 substrate, still bind to the D-LH2-
binding pocket within the FLuc active site, greatly complicating1060 Chemistry & Biology 19, 1060–1072, August 24, 2012 ª2012 Elthe interpretation of assay results (Auld et al., 2008a, 2010;
Keiser et al., 2007). Further, in FLuc reporter gene assays
(RGAs) these inhibitors can function within the cell to increase
the half-life of ectopically expressed FLuc enzyme, leading to
an increase in luciferase activity that can appear indistinguish-
able from reporter gene transcriptional activation (Auld et al.,
2008a, 2009a; Thompson et al., 1991). This has prompted a
re-evaluation of compounds reported to mediate biological
processes when the origins of compound activity are derived
from luciferase-based cellular assays (Herbst et al., 2009; Lys-
siotis et al., 2009; Sotoca et al., 2010). An accurate interpretation
of PubChem data, or any data from luciferase assays used in
small molecule screening, benefits from an understanding of
the FLuc inhibition profile of the compound library.
The prevalence of luciferase inhibitors among active
compounds identified from FLuc RGAs underscores the need
for unambiguous strategies to detect compounds that directly
affect the FLuc reporter. We determined IC50 values for the entire
publically available Molecular Libraries Small Molecule Reposi-
tory (MLSMR) of >300,000 compounds using a FLuc assay
that is sensitive to multiple modes of inhibition (MOI). Here, we
describe the chemotypes associated with FLuc inhibition, and
for a representative set of compounds, we analyze and describe
their MOI, as well as the activity, in prototypical FLuc RGAs. We
also define general principles applicable to the behavior of
FLuc inhibitors in cell-based assays and identify specific strate-
gies to stringently discriminate compound activity resulting from
reporter interferences from that of targeted biological effects.RESULTS
Profiling Statistics and Library Activity
To create a bioactivity profile of luciferase inhibitors, we
screened approximately 360,000 compounds listed in the Pub-
Chem database at six concentrations using qHTS (Figure S1A
available online; PubChem Assay Identifier [AID]:588342). A
global view of library activity is gained by categorizing the
concentration response curves (CRCs) obtained from qHTS
into classes such that class 1a CRCs exhibit full inhibition of
enzyme activity, class 1b are partially inhibitory at the highest
concentration tested, and classes 2a, 2b, and 3 have incomplete
CRCs (Inglese et al., 2006; Shukla et al., 2009). In addition, the
generation of IC50s for each compound allows us to enumeratesevier Ltd All rights reserved
Table 1. Distribution of Inhibition Activity
Activity Distribution
CRC Classification
1a 1b Unqualified 2a 2b Unqualified 3
Activation No. of samples 0 1 0 2 12 0 0
Inhibition No. of samples 5,306 2,191 123 5,772 19,938 493 10,062
Library (%) 1.46 0.60 0.03 1.58 5.48 0.14 2.76
Activators composed <0.004%of the activity. Unqualified, CRCs of lower quality in each of the class 1 or 2 CRCdata sets using a <50%efficacy cutoff.
The total number of inactive compounds was 320,205 (87.94%). Supported by Figure S1 and Table S2.
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chemotypes. For our profiling effort we utilized a biochemical
assay with purified FLuc in the presence of KM concentrations
of substrates. This assay condition is sensitive to identifying
competitive inhibitors that form an intracellular E,I complex in
the absence of excess D-LH2 in FLuc cell-based assays. The
biochemical assay thus differs from that used in our previous
FLuc effort, which employed [D-LH2] >> KM, a condition
commonly used in cell-free assays (Auld et al., 2008a, 2009b).
We found that a total of 43,885 compounds (12% of the
library) inhibited FLuc, with a significant fraction of this activity
(30%) associated with potent and efficacious CRCs (e.g., class
1a, 1b, and 2a CRCs; Figures S1B and S1C; Table 1). These
high-quality CRCs were used to identify scaffolds, and SAR
was further developed by considering related inactive or weakly
active structures. Greater than 5,300 compounds had class 1a
CRCs, 168 of which exhibited potencies <100 nM, with some
having single-digit nM potencies. An additional 30,000 com-
pounds showed weak inhibitory activity (CRC classes 2b and
3; Table 1). Retrospective analysis of the data at a single concen-
tration yielded hit rates of 5% and 1.8% at 11 and 2.3 mM,
respectively. Although it is possible that some of the compounds
that appear to inhibit FLuc could simply quench light, we believe
this to be a relatively rare occurrence. Direct activation of the
FLuc enzyme was observed for <20 compounds; however, this
was not pursued in follow-up studies, as in each case the CRC
was either low quality or low efficacy.
Chemotype Analysis of Actives
Compounds were clustered based on structural similarity to
identify common chemotypes. Prominent clusters previously
observed (Auld et al., 2008a), including benzothiazoles, benzox-
azoles, benzimidazoles, and oxadiazoles, were again identified
here; however, additional chemotypes, which included hydra-
zines and benzoic acids, among others, were also found (Fig-
ure 1; Figure S2A). A hierarchal scaffold-tree-based method
was used to visualize activity among root chemical structures
containing simple rings (Schuffenhauer et al., 2007). A represen-
tation of the potency distribution for compounds found among
132 root structures is shown in Figure 1A (see also Table S2).
The maximum common structure analysis supported that thia-
zoles, imidazoles, and oxadiazoles are among the prevalent
ring structures found in FLuc inhibitors (Figure 1B, i, iii, and xiii,
respectively). The ring system analysis also scored pyridine (Fig-
ure 1B, ii)—found in quinoline-containing compounds previously
identified as FLuc inhibitors (Auld et al., 2008a)—with nearly the
same frequency as thiazole, thus broadening this initial finding to
simpler nitrogen-containing rings. The five member rings furan,Chemistry & Biology 19, 1060–thiophene, pyrazole, and pyrrole (Figure 1B, v, vii, iv, and vi)
were nearly equally represented, with frequencies greater than
either oxazoles, oxadiazoles, or thiadiazole rings (Figure 1B,
xi–xiv). Interestingly, many oxazole- or oxadiazole-containing
compounds were limited to compounds in which these ring
systems were flanked with at least one aryl substituent, most
typically two aryl substituents, with the most potent compounds
often containing simple aryl substitutions (e.g., methyl, methoxy,
carboxy, and halogens). The ring structures pyrimidine, dihydro-
dioxine, and dioxole (Figure 1B, viii, ix, and x), integral to quina-
zoline, benzodioxine, and piperonyl scaffolds, respectively, were
also notable among inhibitors. A closer examination of some of
these scaffold clusters is shown in Figure 1C, depicting highly
potent compounds (compounds 1, 3, 5, 7, and 9) alongside their
weaker analogs (compounds 2, 4, 6, 8, and 10). Readily apparent
is that small, planar, linear structures are a feature of many
potent compounds, whereas angular (e.g., 6 and 10) and/or
larger branched-type configurations (e.g., 2 and 8) show weaker
activity. Notably, the ring-system analysis, when applied to
a biochemical assay that used fluorescence detection, identified
an entirely unique set of scaffolds demonstrating ring structure
SAR consistent with fluorescent interference (PubChem AID:
540253; Figure S2B) and suggesting that the SAR derived from
the FLuc profiling effort is unique to this enzyme.
Multisubstrate Adduct Inhibitor Formation from Aryl
Carboxylates
Certain benzoic acids appended to a 3,5 diaryl-oxadiazole
scaffold are potent FLuc inhibitors with the capacity to form a
FLuc-catalyzed MAI (Auld et al., 2008a, 2009b). The library
used for this qHTS contained 928 ortho-, 722 meta-, and 1,394
para-substituted benzoic acids (regardless of the linker group).
Of the 168 compounds showing IC50s < 100 nM, 26 contained
a benzoic acid group (Figure 2), many of which contained acyclic
linkers bridging two aryl rings, and one compound contained a
thiophene-2-carboxylate (Figure 2, compound 22). The majority
of the carboxylates were meta substituted, with six having para
substitutions. Ortho substitution was absent among potent
benzoic-acid containing inhibitors. The regioisomer SAR of the
substituted benzoic acid correlates with observations made
previously for the 3,5 diaryl-oxadiazole scaffold, consistent
with a potency rank order of meta > para >> ortho for the benzoic
acid substituent (Auld et al., 2009a, 2010). The regioisomer
selectivity of 3,5 diaryl-oxadiazoles can be explained by near-
attack conformer (NAC) positioning of the carboxylate to pro-
mote nucleophilic displacement of pyrophosphate from ATP
with subsequent formation of a potent multisubstrate adduct
inhibitor (MAI; Auld et al., 2010).1072, August 24, 2012 ª2012 Elsevier Ltd All rights reserved 1061
Figure 1. Scaffold Analysis of FLuc Inhibitors
(A) Primary root scaffold analysis and associated potency distribution for compounds associated with these scaffolds. The clustering was based on the high-
quality CRCs (classes 1a, 1b, or 2a) with maximum inhibition values of >50%. Scaffolds at the bottom of the graph contain as few as five members, whereas
scaffolds at the top of the graph contain >1,000 members.
(B) Root scaffolds composed of heterocycles associated with >200 compounds. Representative scaffolds are shown, the most prominent of which were the
thiazole (i), pyridine (ii, found in quinolines), and imidazole (iii) ring structures. A series of oxadiazoles (xiii) were also prevalent. Also shown here are (iv) pyrazole, (v)
furan, (vi) pyrrole, (vii) thiophene, (viii) pyrimidine, (ix) dihydro-dioxine, (x) dioxole, (xi) isoxazole, (xii) oxazole, and (xiv) thiadiazole.
(C) Potency distribution for the scaffolds i–iii, which were highly populated in the data set. Scaffold levels are shown to the left of the potency heatmap and are
depicted as colored dots, with increasing structural complexity proceeding from left to right (i.e., orange indicating the least complex scaffold level and red the
highest complexity shown here). Potency values are in micromolar, and the compounds are colored based on the scaffold level, which includes the substructure.
Of note, not every compound in the potency distribution analysis achieved the highest level of structural complexity, for example, compounds (5) and (6). An
example of both a potent and a weakly active compound is shown for benzothiazoles (1, 2), quinolines (3, 4), pyridines (5, 6), and benzimidazoles (7, 8), as well as
benzimidazoles fused to other ring systems (9, 10). It was found that generally flat, planar structures weremore potent FLuc inhibitors compared tomore complex,
branched, or highly angular structures. Alternate analysis and support for this data is shown in Figure S2. See also Table S2.
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MAIs, compounds were incubated with equimolar equivalents
of FLuc and excess ATP (2 mM), and the mixture was then
analyzed for the predicted M+1 ion associated with the mass
of the adenylated product. As predicted from the regioisomer1062 Chemistry & Biology 19, 1060–1072, August 24, 2012 ª2012 ElSAR, the majority of the compounds with meta carboxylates
were conclusively found to form an adduct (14/16). The only
compounds of this potent class that did not show any evidence
of adduct formation were para-substituted carboxylates (com-
pounds 2 and 18, Figure 2A; Table S3), indicating the high affinitysevier Ltd All rights reserved
Figure 2. Potent Benzoic Acid-Containing Compounds
(A) Potency of compounds, indicated in parenthesis, with a benzoic acid core. Those found to form a MAI are noted. For compounds categorized as ‘‘incon-
clusive,’’ one or more LC/MS traces could not confirm the adenylate product or only a weak peak for the adenylated product was observed. n.d., not determined.
(B) Compounds from the 151 selected for follow-up analysis that were also subjected to LC/MS analysis. Compounds were all found to form the MAI unless
otherwise noted. Data supporting these findings are provided in Table S3 and Figure S3.
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perhaps by interactions acquired by spanning both D-LH2 and
ATP pockets. By comparison, para carboxylate compounds 19
and 21 formed the adenylate adduct. Overlaying 19 and 21
with meta and para oxadiazole analogs suggests that for
a para carboxylate to engage in nucleophilic displacement of
PPi, energetically unfavorable rotation of the distal phenyl group
within the D-LH2 pocket is required. However, the acyclic linkers
of 19 and 21 can achieve a suitable overlay without phenyl group
rotation, explaining MAI formation by these specific para-
substituted compounds (Figure S3). Overall, these benzoic acids
illustrate the range of chemotypes capable of MAI formation.Chemistry & Biology 19, 1060–Characterization of Representative Inhibitors
To gain mechanistic insights into how these compounds inhibit
FLuc and manifest this inhibition in cell-based assays, we
selected 151 compounds representing prominent chemotypes
for additional studies. To determine if any of the selected
compounds were promiscuous bioluminescent inhibitors, 147
were tested in the Renilla reniformis luciferase (RLuc) assay,
with 80% (122 compounds) found to be inactive (highest
concentration tested = 57.5 mM). The few that did appear active
had IC50sR 20 mM in the RLuc assay and were among the least
potent inhibitors of FLuc (IC50s of 20 mM). Two RLuc-active
compounds were benzenesulfonamides (PubChem Compound1072, August 24, 2012 ª2012 Elsevier Ltd All rights reserved 1063
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Analysis of Firefly Luciferase InhibitorsIdentifier [CIDs]: 1105141 and 1087370) that bore structural
similarity to the positive control inhibitor used in the RLuc assay
(BTS, IC50 = 12 mM; Auld et al., 2009a). In addition, a compound
with a unique methylimino-thiazole core (Pubchem CID:
16195963) had a potency of 30 mM against RLuc (40 ± 10 nM
against FLuc). The specificity of FLuc inhibition demonstrated
by these compounds is in general agreement with the observa-
tion that FLuc inhibitors are selectively enriched as active
compounds in FLuc-based assays and not in assays employing
other reporters or detection technologies (Auld et al., 2008b).
FLuc inhibitors that form MAIs have a reduced potency in the
presence of free coenzyme A (CoASH), presumably because of
FLuc-catalyzed thiolytic cleavage of the mixed anhydride of
the MAI (Auld et al., 2010). Addition of a high concentration
(500 mM) of CoASH into the detection buffer significantly weak-
ened the potency of 13 of the 151 compounds tested, all of which
were found to be competitive with D-LH2 (Figure 3A, compound
4). Notably, these compounds contained a diaryl structure with
anm-COOH group, and liquid chromatography-mass spectrom-
etry (LC-MS) confirmed MAI formation (Figure 2B). Interestingly,
for a carboxylate-containing benzothiazole resembling D-LH2
(Figure 2B, compound 24), CoASH caused a 65-fold potency
reduction, though the LC-MS analysis showed only a weak
peak for the adenylated adduct.
Many compounds competitive with D-LH2 are simple
substituted benzothiazole scaffolds (Figures 3A, 3B, and 3D),
themajority of which (23/25) becomemore potent in the presence
of saturating ATP (Figure 3A, compound 3; Figures 3C and 3D).
The X-ray cocrystal structure for a representative benzothiazole
(Protein Data Bank [PDB] ID code: 4E5D) confirms binding of
this chemotype to the D-LH2 pocket (Figure S4), which mainly
consists of pp interactions with F247 (Figure 4). The ligand
does not form direct hydrogen bonds with the protein but is teth-
ered by water-mediated contacts between the benzothiazole
nitrogen and the carbonyl oxygen of G246 and hydroxyl of
S347. As such, there are no hydrogen bonds to stabilize, and
the loop between S314 to L319 is disordered as we have also
observedwith anMAI (Auld et al., 2010). Therefore, the conforma-
tion of this loop is similar to the apo form of luciferase that we
previously reported (PDB ID code: 3IEF). Taken together with
MOI analysis, this data points to an uncompetitive inhibition
mode for these benzothiazoles, with respect to ATP. Additionally,
for 73 compounds (of 151 total tested) that showed noncompeti-
tive inhibition with respect to D-LH2, nearly one-third (27 com-
pounds) were also observed to contain a benzothiazole. Structur-
ally, these benzothiazoles are characterized by a polar or more
structurally complex substitution pattern (Figure 3D, compounds
5 and 6) compared to those of the D-LH2-competitive class.
Consistent with inhibitor-based enzyme stabilization, we
observed increases in FLuc Tm values for representative benzo-
thiazoles (Figures 4C and 4D). TheDTm values ranged from1C
to as high as 7.6C and correlated with the IC50s of these
inhibitors (r2 > 0.94; Figure 4D). The presence of saturating
(2 mM) ATP led to generally higher DTm values (these were
between 1C and 5C higher in the presence of ATP). This is
consistent with high ATP improving the binding interactions of
benzothiazole inhibitors to FLuc. The data in the presence of
high ATP is probably more representative of the stabilization
occurring intracellularly upon FLuc inhibitor binding.1064 Chemistry & Biology 19, 1060–1072, August 24, 2012 ª2012 ElOf the follow-up compounds tested, ATP-competitive inhibi-
tors were fewer in number (16) than D-LH2-competitive inhibitors
(42). Most interesting, however, was a quinolinyl benzimidazole
(IC50 = 70 ± 10 nM), the potency of which was significantly
reduced by either ATP or D-LH2 (Figure 3A, compound 2, CID:
4216593). This compound contains both a benzimidazole,
a moiety competitive with D-LH2 (Auld et al., 2008a), as well as
a quinoline, which is competitive with ATP (Auld et al., 2008a;
Fry et al., 1994) and is structurally consistent with the compound
occupying both substrate pockets. Interestingly, CID: 4216593
is listed as active in 27 assays in PubChem (as of December
2011), 70% of which are based on FLuc (National Center for
Biotechnology Information).
Consequences of FLuc Inhibition in RGAs
Our previous work addressed how FLuc inhibitors caused an
increase in FLuc signal in RGAs by FLuc inhibitor-based stabili-
zation (Auld et al., 2009a, 2010). To see how the 151 FLuc inhib-
itors with known MOI behaved in FLuc RGAs, we tested these in
two assays, the pFLucUGA190UGA assay (Auld et al., 2009a) and
the miR-21 assay (PubChem AID 2288), which were designed to
identify compounds that increase FLuc expression, presumably
by targeted pathway modulation. In both of these assays, FLuc
inhibitors could also generate an increase in FLuc signal by
FLuc inhibitor-based stabilization. We found that a significant
percentage of the compounds caused luminescence to
increase: 65% in the miR21 assay (Gumireddy et al., 2008)
and 25% in the FLuc190UGA read-through assay (Auld et al.,
2009a) using either a 48 or 72 hr compound incubation time.
Approximately two-thirds of the compounds that were active in
the miR-21 assay were also active in the FLuc190UGA read-
through assay. Only one compound in the read-through assay
was classified as inactive in the miR-21 assay.
To observe FLuc enzymatic activity in the cell-based assays,
the composition of the detection reagents (e.g., [D-LH2 or ATP]
and/or [CoASH]) has to be sufficient to overcome the FLuc inhib-
itor binding. The detection reagents used in this study increased
the IC50 of the inhibitors (reduced the potency) by >5-fold for
30%–40% of the inhibitors in a purified FLuc assay (Figure S5).
Compounds that remained potent in detection reagent were
found to be either highly potent against the enzyme, with only
slight effects on IC50 when a single substrate was present in
excess, or those that showed an uncompetitive inhibition
mode (Figure S5).
Inhibitors leading to activation in the cell-based assays
covered a range of MOIs as determined with purified FLuc in
biochemical assays, with competitive, noncompetitive, and
uncompetitive inhibitors all resulting in varying degrees of activa-
tion in the cell-based assays (Figure 5A). Although the CRC
varied depending on the cell-based assay, compounds that
are competitive with one of the FLuc substrates often gave rise
to strong activation in the cell-based miR-21 assay and were
highly potent FLuc inhibitors (e.g., CID: 16015828, AC50 =
10 nM and CID 5456435, AC50 = 4 nM, Figure S5), which re-
mained active in the presence of detection reagents. Several
inhibitors did not demonstrate activation in the cell-based
assays, possibly because of cell impermeability, failure to suffi-
ciently stabilize FLuc from intracellular degradation, or because
they destabilized FLuc in a cellular context (Nishiya et al., 2009).sevier Ltd All rights reserved
Figure 3. Substrate Competition Analysis of FLuc Inhibitors in Enzyme Assays
(A) Example data for compounds competitive with D-LH2 (1), competitive with both D-LH2 and ATP (2, CID:4216593), competitive with D-LH2 and uncompetitive
with ATP (3), and a compound showing weaker potency with CoASH because of MAI formation (4). The data are the average of replicate determinations
(n = 3 or 4), where error bars represent the SD.
(B and C) Potency (IC50) shifts for each of the 151 follow-up compounds. The x axis shows the IC50 (in micromolar) of each compound under conditions in which
both substrates are held near their KM concentrations. The y axis indicates the fold-shift in potency obtained when either D-LH2 is present at high concentration
(B, 1 mM; Fold = IC50 at high D-LH2/IC50 at KM D-LH2) or when ATP is present at high concentration (C, 1 mM; Fold = IC50 at high ATP/IC50 at KM ATP). Red dots
represent compounds that became>3-fold less potent in the presence of either high D-LH2 (B) or ATP (C) (i.e., IC50 increased by >3-foldwith high concentration of
substrate). Orange dots indicate compounds whose potency not only decreased in the presence of high concentrations of D-LH2 or ATP but also decreased
by >3-fold in the presence of high CoASH (500 mM i.e., IC50 increased by >3-fold in presence of 500 mMCoASH and KM concentrations of D-LH2 and ATP). Blue
dots are those compounds that became >3-fold more potent in the presence of high ATP (i.e., IC50 decreased by >3-fold). The horizontal lines represent a 3-fold
shift in potency in either direction.
(D) Compounds associated with the orange dots (and whose potency decreased in the presence of high concentrations of CoASH and D-luciferin) were found to
have an aryl carboxylate. Compounds associated with blue dots (and became more potent in the presence of high concentrations of ATP) largely contained
a benzothiazole scaffold. A single compound (2, CID:4216593) was found to have the highest shift in potency in both high D-luciferin and high ATP conditions.
5 and 6, example compounds showing either mixed or noncompetitive behavior, respectively. 7i, 7ii, and 8, examples of compounds demonstrating competitive
behavior with ATP. Compound 9, an example compound that is more potent with high ATP concentration. Supported by Figure S5.
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Figure 4. X-Ray Structure of a Benzothiazole-FLuc Cocrystal
(A) Interactions of a benzothiazole (magenta) within the D-LH2 pocket of FLuc. Aromatic stacking interactions between the benzothiazole core and F247 are
observed. A water-mediated H-bond was formed between benzothiazole nitrogen and G246 backbone carbonyl oxygen and S347 hydroxyl, as shown by the red
dotted line. Protein residues are shown in cyan; supported by Table S1 and Figure S4.
(B) Overlay of the benzothiazole (magenta) with the FLuc-bound structure of PTC124-AMP (PDB ID code: 3IES; orange) showing occupation of the D-LH2 pocket
by the benzothiazole with no overlap into the AMP binding region of FLuc. The binding pocket is depicted as a semitransparent yellow surface. These figures were
prepared with the program VIDA (OpenEye Scientific Software).
(C) Representative simple benzothiazoles and example thermal shift data assayed in the presence of 2 mM ATP.
(D) The DTm obtained at 100 mM compound in the presence (open squares) or absence (solid circles) of 2 mM ATP plotted against the potency of each
benzothiazole (shown in C).
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pounds were active in the two cell-based assays, the types of
CRCs generated by these compounds could differ between
the assays (examples are shown in Figure 5B), likely because
of protocol differences, as discussed below.
DISCUSSION
In this study we provide a complete profile of FLuc inhibitory
activity for each of the 360,864 compounds in the MLSMR.
Approximately 4% of the FLuc inhibitors displayed high-quality
CRCs with potencies generally <10 mM. By comparison, our
previous FLuc profiling campaign used higher D-LH2 concentra-
tions in the assay (Auld et al., 2008a). Out of the 8,233
compounds identified as FLuc inhibitors in this study that were
also screened in our previous effort, only 1,971 (24%) were
active in the previous, high-concentration D-LH2 assay. These1066 Chemistry & Biology 19, 1060–1072, August 24, 2012 ª2012 Elresults, available in PubChem, underscore the pervasiveness
of compounds that inhibit FLuc in compound libraries used for
screening and indicate that many of these compounds are
competitive with D-LH2.
The enrichment of potent FLuc inhibitors in FLuc-basedassays
carries important consequences for RGAs as these can easily
confound and overwhelm marginally active, target-directed
compounds. For example, examination of assays listed in Pub-
Chem indicated that FLuc inhibitors can comprise more than
half the hits derived from FLuc-based assays (Auld et al.,
2008b) and reports have noted higher enrichments, approaching
98% (Lyssiotis et al., 2009; Younis et al., 2010). Nonetheless,
such chemotypes have been considered as lead series, in part
based on suggestive secondary assay data, although the target
underlying the activity has yet to be identified (Manuvakhova
et al., 2011; Xiao et al., 2011). Potent FLuc inhibitors have also
been characterized from natural product extracts (Cruz et al.,sevier Ltd All rights reserved
Figure 5. Apparent Activation of FLuc Signal Associated with FLuc Inhibitors
(A) Heatmap colored by activity in the indicated cell-based assay. Two-thirds of the follow-up compounds tested were active in at least one of the cell-based
assays tested. Except for two compounds (out of 151), compounds active in the read-through assays (UGA) at 48/72 hr were also active in the miR-21 assay. For
the read-through assay, regardless of the MOI, FLuc inhibitors generally produced an activation-type curve. Of note, very few FLuc inhibitors produced an
inhibitory CRC in these assays, as the assays were developed and optimized to identify compounds that caused activation of FLuc signal.
(B) CRCs for select FLuc inhibitors comparing their activity in the cell-based assays and biochemical assay. FLuc inhibitors with different MOIs (see Figure 2)
commonly exhibit inhibition of FLuc in the biochemical assay with KM concentrations of substrates and produce activation or bell-shaped curves in cell-based
assays. The data are the average of replicate determinations (n = 3 or 4, enzyme assay; n = 2 or 3 for cell-based assay), where error bars represent the SD.
Supported by Figure S6.
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results (Pang et al., 2011). The data and findings provided by
our work can be used to triage or annotate FLuc inhibitors from
candidate hits, thereby aiding in the prioritization of compounds
chosen for follow-up investigation, and importantly reiterates
the value of redundancy in reporter outputs (Auld et al., 2009a).
FLuc Inhibitors Defined
Compounds inhibiting FLuc have a defined SAR and do not
demonstrate inhibition of unrelated luciferases, such as Renilla
luciferase. Inhibitors of FLuc tend to be small (for the high-quality
inhibitor CRC classes the MWavg = 325.8 ± 63.3, maximum =Chemistry & Biology 19, 1060–898.8, minimum 122.17; additional physicochemical parameters
are given in Table S2), linear, planar structures and, from scaffold
analysis, commonly contain a thiazole, imidazole, oxadiazole, or
pyridine ring. Scaffold analysis indicates the fusion of these
5-membered rings are often observed in benzothiazoles, ben-
zoxazoles, benzimidazoles, and oxadiazoles, whereas hydra-
zines can be found to bridge aromatic substituents, such as
benzoic acids.
FLuc inhibitors act through a number of MOIs, some resem-
bling and acting as competitive inhibitors of D-LH2, such as ben-
zothiazoles, whereas others, including a significant number
belonging to this chemotype, are noncompetitive with D-LH2.1072, August 24, 2012 ª2012 Elsevier Ltd All rights reserved 1067
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(e.g., CID: 4216593), or only ATP, such as the hydrazine-contain-
ing compound CID: 16193026. For a subset of benzothiazole-
containing compounds (e.g., CID: 976322), ATP was found to
enhance inhibitor binding.
Enzymatic adenylation of a compound with an appropriately
positioned carboxylate represents a unique mechanism of FLuc
inhibition through MAI formation. Although typically a rare event,
difficult to achieve by design of synthetic inhibitors (Inglese and
Benkovic, 1991), MAIs occur relatively frequently in our study
and, not surprisingly, are among the most potent FLuc inhibitors.
FLuc-catalyzed formation of an MAI requires some degree of
substrate specificity, as seen for oxadiazoles meta substituted
to benzoic acids (Auld et al., 2010). However, in the large-scale
profiling data shown here, we observed that acyclic linkers can
substitute for 5-membered ring systems, bridging benzoic acids
to other aromatic rings. Further, the more flexible acyclic linkers
allow some para-substituted benzoic acids to engage in MAI
formation. A diagnostic test for MAI formation is the approxi-
mately 100-fold potency decrease shown by an FLuc inhibitor
in the presence of high concentrations of CoASH, likely attribut-
able to the thiolytic reaction similar to that between CoASH and
L-AMP (Fraga et al., 2004, 2005). Because of the high potency of
FLuc MAIs, one must be careful to consider the purity of the
compound sample, as even trace contaminates that form an
MAI could lead to misleading results.
Behavior of FLuc Inhibitory Compounds in Cell-Based
FLuc RGAs
FLuc enzyme inhibitors can be detected in FLuc RGAs as either
inhibitors or activators of FLuc signal/expression, producing
inhibition, activation, or bell-shaped CRCs. The shape and direc-
tion of the CRC generated by a FLuc inhibitor in a FLuc RGA
depends on a number of properties: the IC50, the compound’s
MOI, the assay format, and the detection reagent used in the
assay (Auld et al., 2008b). Previously, we found that prolonged
compound incubation times (48 or 72 hr) increase the level of
apparent activation of FLuc and thus the number of apparent
activator compounds (Auld et al., 2008b, 2009a). At shorter
incubation times (<10 hr) in cell-based assays it is unlikely that
significant apparent activation will be observed with wild-type
FLuc as a reporter. In addition, the type of detection reagent
used to quantify FLuc signal can influence the level of activation
detected because of FLuc-inhibitor-based stabilization (Peltz
et al., 2009). Detection reagents that contain high concentrations
of CoASH (BrightGlo – Promega, Madison, WI, USA; BriteLite -
Perkin Elmer, Waltham, MA, USA) are commonly used in HTS
because addition of CoASH enhances FLuc signal. Under such
conditions MAIs would be converted to low potency CoA
adducts (Auld et al., 2010) easily competed off the enzyme by
excess concentrations of D-LH2 and ATP also found in these
detection reagents.
In this study, we found that some cell-based FLuc assays were
more susceptible than others in identifying FLuc inhibitors. For
example, in an assay designed to respond to perturbation of
a biological interaction with an increase in FLuc reporter activity
(miR-21 assay), approximately twice as many FLuc inhibitors
were found to be active compared to a similarly designed
read-through assay. In addition, FLuc inhibitors in the miR-211068 Chemistry & Biology 19, 1060–1072, August 24, 2012 ª2012 Elassay generated bell-shaped or activation-type CRCs, whereas
the majority of these compounds generated activation-type
CRCs in the read-through assay. Specifically, of the 36
compounds that generated activation CRCs in the read-through
assay at the 72 hr time point, 19 generated bell-shaped curves in
the miR-21 assay (Figure S6). One main difference in the proto-
cols between the two assays is that our read-through assay
involves wash steps prior to addition of detection reagent, which
effectively removes excess compound (equilibrated between
cells and culture medium). This effectively enhances the level
of uninhibited FLuc upon addition of detection reagent and cell
lysis, thereby leading to greater FLuc signal and activation-
type sigmoidal CRCs. Bell-shaped CRCs are composite
responses generated by the stabilization of FLuc in the cell by
the inhibitory compound at low concentrations, which give rise
to apparent activation in FLuc signal, followed by inhibition and
a decrease in reporter activity at higher concentrations of inhib-
itor (Figure 5A, compounds 1 and 5, blue curve). Another differ-
ence between the two assays is that the miR-21 assay ex-
pressed wild-type FLuc, whereas functional FLuc expressed in
the read-through assay is produced by misincorporation of an
amino acid at codon 190 (which is a nonsense codon in the
assay). It is thus possible that the potency of certain inhibitors
against this mutant FLuc could be different than for the wild-
type enzyme. The effect that such assay format differences
have on whether a given compound is identified as a FLuc inhib-
itor limits the utility of cell-based FLuc assays as counterscreens.
We have found that FLuc RGAs in which there is a low-level of
basal FLuc expression seem especially susceptible to FLuc
inhibitory compounds that appear as ‘‘activators’’ in the assay.
This is characteristic of the two cell-based assays described in
this paper—the miR-21 and read-through assays—both opti-
mized to identify activators of FLuc expression/activity. The large
number of FLuc inhibitors identified when using these assays to
screen a compound library is likely due to FLuc inhibitor-based
stabilization, a phenomenon that we and others have previously
described (Auld et al., 2008b, 2009a; Thompson et al., 1991) and
confirmed here with benzothiazoles. A stronger than expected
activation relative to control compounds, so-called ‘‘super acti-
vation,’’ can be an indication that inhibitor-based stabilization
is operating (Sotoca et al., 2010). If the activation effect parallels
the concentration range observed for the inhibition of purified
FLuc enzyme, and if the SAR for the cell-based activation activity
tracks with the inhibition of FLuc, then inhibitor-based stabiliza-
tion is the likely mechanism for cellular activity (Thorne et al.,
2010). We have observed that assays in which the basal pool
of FLuc is very low, FLuc inhibitors are readily identified, as
activity from FLuc inhibitor-based stabilization can represent
a significant component of the assay signal. By comparison, in
assays with significantly higher levels of basal FLuc expression,
FLuc inhibitor-based stabilization may not be as apparent. In
general, the susceptibility of a given FLuc RGA to modulation
by FLuc inhibitors can be evaluated using compounds described
in this study, many of which are commercially available.
In our profiling effort we also encountered compounds that
were inactive against purified FLuc but could potentially be con-
verted to FLuc inhibitors in cells, through cellular metabolic
processes. The simplest case is an appropriately positioned
ester, where hydrolysis by intracellular esterases would yieldsevier Ltd All rights reserved
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enylation of the compound by FLuc and stabilization of FLuc by
the hydrolyzed ester metabolite of this compound. This brings up
an important point: although our profiling campaign and MOI
analysis of FLuc inhibitors is the most comprehensive to date,
complete reliance on this database for identification of all poten-
tial FLuc inhibitors is not currently possible, as exemplified
by compounds that are intracellularly metabolized into FLuc
inhibitors.
FLuc inhibitors uncompetitive with ATP, which in this study
were commonly simple benzothiazoles that likely bind to the
FLuc luciferin pocket, may also behave differently in cell-based
assays compared to a FLuc enzyme assay. These compounds
are likely to show more potent binding to FLuc in cells where
ATP levels are high and D-LH2 is absent and thus appear more
potent in cell-based FLuc RGAs than in a FLuc enzyme assay
with KM concentrations of substrates.
Assessing the Impact of FLuc Inhibition in Cell-Based
Assays
Alternative strategies can be used to identify FLuc inhibitors and
these differ depending on whether one is searching for agonists
or antagonists of the luciferase signal (Figure 6, tier 1). The first
step in determining if compounds active in a cell-based FLuc
RGA are FLuc inhibitors is to evaluate their activity in the
biochemical assay used in this study—a purified FLuc assay
using KM concentrations of substrates (Figure 6, tier 2). To iden-
tify compounds that are uncompetitive inhibitors with respect to
ATP, it is necessary to run the FLuc biochemical assay in the
presence of low D-LH2 (e.g., 10 mM D-LH2) and high ATP (e.g.,
1 mM). Preincubation of the compound with FLuc in the pres-
ence of high ATP is another test for FLuc inhibitors. Commercial
detection reagents should not be used to determine FLuc
inhibitor potency as these contain excess concentrations of
substrates of a proprietary composition that can influence the
apparent potency of tested compounds.
The choice of detection reagent depends on the desiredmode
of action in the cell-based assay. For agonist assays (Figure 6,
tier 1, right) an option is to instead add D-LH2 alone and rely
on intracellular ATP levels to measure unbound intracellular
FLuc. For example, if the signal allows for this format, 10 to
30 mM D-LH2 is added shortly after cell seeding and luciferase
activity is detected in a nonlytic mode from live cells at multiple
time points (Didiot et al., 2011). In this mode, cell-permeable
FLuc inhibitors will be apparent at early time points. The signal
will be lower when substituting D-LH2 for detection reagent,
but given the extremely low background of luminescence, the
signal-to-background of the assay is often acceptable. Possible
caveats to adding D-LH2 to live cells include adverse effects on
cell viability and that the assay may identify compounds that
modulate ATP levels. For antagonist assays (Figure 6, tier 1,
left), it is necessary to use detection reagents to reduce the
number of competitive inhibitors identified as actives in the
assay. In either case, if changing the detection reagent (e.g.,
from BrightGlo to D-LH2) shows a marked effect on the pharma-
cology of compounds (activation level, inhibition level, or AC50),
then luciferase interference is likely present.
The ideal experiment to exclude FLuc inhibitors is to develop
an orthogonal reporter system (e.g., the same assay but withChemistry & Biology 19, 1060–an alternate reporter; Jang et al., 2012), preferably in an isogenic
cell line, to confirm the nature of actives identified in a FLuc
RGA before any conclusions on compound activity are made.
This should greatly simplify the characterization of actives
arising from FLuc-cell based assays and can be placed at the
initial screening stage, if practical, or used at a subsequent
step (Figure 6, tiers 1 and 2). Alternative reporters include RLuc
(Roda et al., 2009), b-lactamase (Zlokarnik et al., 1998), and
Gaussia luciferase (Maguire et al., 2009). Accurately identifying
compounds as FLuc inhibitors can be complicated, as demon-
strated here and in other studies (Auld et al., 2008b, 2009a,
2010), and thus it is especially important not to develop struc-
ture-activity relationships (SAR) solely derived from compound
activity in a cell-based FLuc RGA, as this significantly increases
the likelihood of optimizing compounds for FLuc inhibitory
activity instead of activity for the intended target. In cases in
which compounds appear to be FLuc enzyme inhibitors but
also remain active in the orthogonal RGA, the orthogonal assay
should be used to guide chemical optimization of the series.
Finally, the use of nonenzymatic reporters, such as fluorescent
proteins, will help eliminate the complications of enzyme inhibi-
tors, but it is important to note that such assays also require suit-
able orthogonal reporter assays to identify fluorescent interfer-
ences (e.g., quenching or compound fluorescence).
SIGNIFICANCE
The hypothesis that firefly luciferase (FLuc) signal modula-
tion is due to a compound interacting with a particular
target/pathway demands rigorous confirmation before
secondary or tertiary assays are investigated to avoid
deceptive leads. The profiling database developed in this
study should be used in combination with experiments that
specifically test for reporter interference, in addition to
confirmation of activity using orthogonal assays, before per-
forming secondary assays or in vivo models that try to build
on assumed target activity. With this study, we aim (1) to
provide a more highly resolved understanding of the various
mechanisms of FLuc inhibition by compounds commonly
found in screening libraries and (2) to provide researchers
with a methodology for successfully identifying compounds
that genuinely affect the biology of interest in FLuc cell-
based assays. With this study as a guide, discerning utiliza-
tion of FLuc as an assay reporter can facilitate the identifica-
tion of viable leads.
EXPERIMENTAL PROCEDURES
Reagents
See the Supplemental Experimental Procedures for source of reagents.
Preparation of Compound Libraries and Control Plates
From the National Institutes of Health Molecular Libraries Small Molecule
Repository 364,105 total compounds (360,864 unique compounds) were
titrated at seven concentrations as previously described (Yasgar et al., 2008)
and further elaborated on in the Supplemental Experimental Procedures.
Luciferase Assay and qHTS Data Analysis
The luciferase assay used 10 mMATP andD-LH2 andwas performed in Greiner
MB white 1536-well plates as described (Auld et al., 2010). Also refer to the
Supplemental Experimental Procedures.1072, August 24, 2012 ª2012 Elsevier Ltd All rights reserved 1069
Figure 6. Strategies for Identifying Luciferase Inhibitor Interference
Actives identified in agonist (tier 1, right) or antagonist (tier 1, left) cell-based assays should be tested in the FLuc enzyme assay using KM levels of substrates, as a
preliminary filter for luciferase inhibitors (tier 2, protocol a) and removes detection reagent dependent-activity. One can then directly test compounds in a suitable
orthogonal reporter system if it is available (right path), or if no such assay is readily available, compound activity can be analyzed in a series of tests (central path,
tier 3) to determine if FLuc interference exists. In tier 3, protocol b is the FLuc enzyme performed at low D-LH2 (e.g., 10 mM) and saturating ATP, which will help
identify FLuc inhibitors uncompetitive with ATP. If D-LH2 was not already used in the RGA (see tier 1), then protocol c, the RGA assay performed with D-LH2
detection as a time course study, can be used to identify detection reagent-dependent compound activity. Results from our profiling work (PubChemAID 588342)
can also be used as a resource to identify related chemotypes that may act as FLuc inhibitors. If counterscreen assays are used, they should be calibrated with
a few FLuc inhibitors described in this report to determine the relative sensitivity of the assay to FLuc inhibitors.
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Structure-based relationships were examined by a scaffold tree clustering
method (Schuffenhauer et al., 2007). For in-depth MOI analysis, only com-
pounds associated with high-quality CRCs (class 1a, 1b, and 2a) were used.
See the Supplemental Experimental Procedures for further details.
LC/MS of Compounds
Evidence for multisubstrate adduct inhibitor (MAI) formation was obtained with
liquid chromatography/mass spectrometry (LC/MS) using assay conditions1070 Chemistry & Biology 19, 1060–1072, August 24, 2012 ª2012 Elpreviously described (Auld et al., 2010). A detailed LC/MS protocol is
described in the Supplemental Experimental Procedures.
Mode of Inhibition Assays with Purified Firefly Luciferase
To probe the MOI for 151 selected FLuc inhibitors, a 12-point titration of each
compound (final concentrations ranged from 57.5 mM to 0.3 nM) was tested in
luciferase assays as previously described. For MOI assays, one of the sub-
strates was present at a KM concentration, whereas the other was at saturating
concentrations (1 mMATP or 1mMD-luciferin). In addition, the activity of eachsevier Ltd All rights reserved
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Each MOI assay was performed in three separate tests and each compound
was assayed in duplicate in each test.
Renilla Luciferase Biochemical Assay
The RLuc assay was performed as described previously (Auld et al., 2009a).
Briefly, a 12-point titration of each follow-up compoundwas tested in an assay
of 1 nM purified RLuc and 5 mM (KM concentration) of coelenterazine, its
substrate, in a Tris acetate buffer (pH 7.6). BTS (cat #1870, Tocris, Bristol,
UK)—a compound we previously identified as an RLuc inhibitor—was used
as a positive control.
Cell-Based FLuc RGAs
The following cell-based FLuc RGAs were used to study the activity of FLuc
inhibitors in a cellular context: the pFLucUGA190UGA assay (Auld et al.,
2009a) and a miR-21 FLuc assay (48 hr incubation with compound; PubChem
AID 2288).
Crystallization, Data Collection, and Refinement
The determination of FLuc-ligand cocrystal structures has been described
previously (Auld et al., 2010), with details for the FLuc,benzothiazole structure
in the Supplemental Experimental Procedures. Crystallographic data are
provided in Table S1. Coordinates and structure factors have been deposited
in the Protein Data Bank (ID code 4E5D).
Thermal Shift Assay
FLuc was obtained from Sigma-Aldrich (St. Louis, MO, USA; catalog no.
L1792). SYPRO Orange (5000X stock, provided by Life Technologies,
Carlsbad, CA, USA) was used as the environmentally sensitive dye to monitor
FLuc unfolding induced by temperature increase performed on an iQ5
Real-Time PCR Detection system (Bio-Rad, Hercules, CA, USA). Further
details are in the the Supplemental Experimental Procedures.
ACCESSION NUMBERS
Coordinates and structure factors have been deposited in the Protein Data
bank Bank (accession ID code 4E5D).
SUPPLEMENTAL INFORMATION
Supplemental Information includes three tables, six figures, and Supplemental
Experimental Procedures and can be found with this article online at http://
dx.doi.org/10.1016/j.chembiol.2012.07.015.
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